These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38465482)

  • 1. A placebo-controlled, double-blind study evaluating the effect of orally administered polyunsaturated fatty acids on the oclacitinib dose for atopic dogs.
    Schäfer L; Thom N
    Vet Dermatol; 2024 Aug; 35(4):408-417. PubMed ID: 38465482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomised, double-blinded, controlled trial to determine the efficacy of combined therapy of oclacitinib and marine oil extract PCSO-524 in dogs with atopic dermatitis.
    Nishiyama T; Kusakabe M; Imanishi I; Hisano T; Fukamachi T; Taguchi N; Iyori K; Hsiao YH
    Vet Dermatol; 2023 Dec; 34(6):523-531. PubMed ID: 37485602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs.
    Little PR; King VL; Davis KR; Cosgrove SB; Stegemann MR
    Vet Dermatol; 2015 Feb; 26(1):23-30, e7-8. PubMed ID: 25496303
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A blinded, randomized, placebo-controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel®) in client-owned dogs with atopic dermatitis.
    Cosgrove SB; Wren JA; Cleaver DM; Walsh KF; Follis SI; King VI; Tena JK; Stegemann MR
    Vet Dermatol; 2013 Dec; 24(6):587-97, e141-2. PubMed ID: 24581322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of oclacitinib (Apoquel®) compared with prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client-owned dogs in Australia.
    Gadeyne C; Little P; King VL; Edwards N; Davis K; Stegemann MR
    Vet Dermatol; 2014 Dec; 25(6):512-8, e86. PubMed ID: 25109820
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of 0.0584% hydrocortisone aceponate topical spray and systemic oclacitinib combination therapy in dogs with atopic dermatitis: a randomized, double-blinded, placebo-controlled trial.
    Takahashi J; Kanda S; Imanishi I; Hisano T; Fukamachi T; Taguchi N; Momiyama S; Nishiyama S; Motegi T; Iyori K
    Vet Dermatol; 2021 Apr; 32(2):119-e25. PubMed ID: 33185330
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term compassionate use of oclacitinib in dogs with atopic and allergic skin disease: safety, efficacy and quality of life.
    Cosgrove SB; Cleaver DM; King VL; Gilmer AR; Daniels AE; Wren JA; Stegemann MR
    Vet Dermatol; 2015 Jun; 26(3):171-9, e35. PubMed ID: 25688708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis.
    Cosgrove SB; Wren JA; Cleaver DM; Martin DD; Walsh KF; Harfst JA; Follis SL; King VL; Boucher JF; Stegemann MR
    Vet Dermatol; 2013 Oct; 24(5):479-e114. PubMed ID: 23829933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of various treatment options for canine atopic dermatitis: a blinded, randomized, controlled study in a colony of research atopic beagle dogs.
    Marsella R; Ahrens K; Wilkes R; Trujillo A; Dorr M
    Vet Dermatol; 2020 Aug; 31(4):284-e69. PubMed ID: 32301565
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of oclacitinib for the control of feline atopic skin syndrome: correlating plasma concentrations with clinical response.
    Carrasco I; Ferrer L; Puigdemont A
    J Feline Med Surg; 2022 Aug; 24(8):787-793. PubMed ID: 34612749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunomodulatory effect of long-term oclacitinib maleate therapy in dogs with atopic dermatitis.
    De Caro Martins G; da Costa-Val AP; Coura FM; Diamantino GML; Nogueira MM; de Oliveira Melo-Junior OA; Giunchetti RC; da Silveira-Lemos D; Melo MM
    Vet Dermatol; 2022 Apr; 33(2):142-e40. PubMed ID: 34747068
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomised controlled trial testing the rebound-preventing benefit of four days of prednisolone during the induction of oclacitinib therapy in dogs with atopic dermatitis.
    Olivry T; Lokianskiene V; Blanco A; Mestre PD; Bergvall K; Beco L
    Vet Dermatol; 2023 Apr; 34(2):99-106. PubMed ID: 36330780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pilot evaluation of Enterococcus faecium SF68 as adjunctive therapy for oclacitinib-responsive adult atopic dermatitis in dogs.
    Yamazaki C; Rosenkrantz W; Griffin C
    J Small Anim Pract; 2019 Aug; 60(8):499-506. PubMed ID: 31257599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized double-blind clinical trial: Comparison of oclacitinib with a traditional Chinese herbal medicine product (Dihuang Guiqin capsule) in the treatment of canine atopic dermatitis.
    Qin JJ; Zhu H; Song ZW; Hou XJ; Wang XM; Wang L; Li JX
    Res Vet Sci; 2024 May; 171():105221. PubMed ID: 38490043
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A double-blinded, randomized, methylprednisolone-controlled study on the efficacy of oclacitinib in the management of pruritus in cats with nonflea nonfood-induced hypersensitivity dermatitis.
    Noli C; Matricoti I; Schievano C
    Vet Dermatol; 2019 Apr; 30(2):110-e30. PubMed ID: 30656750
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of cyclosporine-sparing effects of polyunsaturated fatty acids in the treatment of canine atopic dermatitis.
    Müller MR; Linek M; Löwenstein C; Röthig A; Doucette K; Thorstensen K; Mueller RS
    Vet J; 2016 Apr; 210():77-81. PubMed ID: 26975448
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The frequency of urinary tract infection and subclinical bacteriuria in dogs with allergic dermatitis treated with oclacitinib: a prospective study.
    Simpson AC; Schissler JR; Rosychuk RAW; Moore AR
    Vet Dermatol; 2017 Oct; 28(5):485-e113. PubMed ID: 28513001
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The role of oclacitinib in the management of ischaemic dermatopathy in four dogs.
    Levy BJ; Linder KE; Olivry T
    Vet Dermatol; 2019 Jun; 30(3):201-e63. PubMed ID: 31006925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of a spot-on formulation containing polyunsaturated fatty acids and essential oils on dogs with atopic dermatitis.
    Blaskovic M; Rosenkrantz W; Neuber A; Sauter-Louis C; Mueller RS
    Vet J; 2014 Jan; 199(1):39-43. PubMed ID: 24355814
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A pilot study on the effect of oclacitinib on epicutaneous sensitization and transepidermal water loss in a colony of atopic beagle dogs.
    Marsella R; Ahrens K
    Vet Dermatol; 2018 Oct; 29(5):439-e146. PubMed ID: 29926994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.